Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex receives CHF5M and 20% share of Neurosterix  Perceptive Advisors leads $63M investment into Neurosterix  Addex contributes portfolio of preclinical neuroscience assets and...

Related Keywords

United States ,Switzerland ,New York ,Geneva ,Genè ,Swiss ,American ,Addex Neurosterix ,Fred Callori ,Jean Philippe Rocher ,Mike Sinclair ,Robert Lutjens ,Tim Dyer ,Mikhail Kalinichev ,Perceptive Life Sciences Fund ,Janssen Pharmaceuticals Inc ,Swiss Exchange ,Nasdaq ,Perceptive Xontogeny Venture Fund ,Hoc Announcement Pursuant ,Perceptive Advisors ,Acorn Bioventures ,Janssen Pharmaceuticals ,Managing Director ,Addex Executive ,Addex Executive Management ,Translational Science ,Executive Management ,Perceptive Xontogeny Venture Funds ,Perceptive Advisor ,American Depositary Shares ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Addex Therapeutic Annual Report ,Addex Therapeutics ,Addex Therapeutic ,Markets ,